Information Provided By:
Fly News Breaks for February 24, 2020
Feb 24, 2020 | 06:40 EDT
JMP Securities analyst Jason Butler raised his price target on Esperion to $191 and kept his Outperform rating, adjusting his model to 100% probability of approval for its Nexletol after the FDA grabted its efficacy and safety label with an expected launch on track for March 30th.
News For ESPR From the Last 2 Days
There are no results for your query ESPR